Last week started with another encouraging announcement for a covid-19 vaccine after Moderna said that its candidate was 94.5% effective in Phase 3 trials. The update came just a week after Pfizer’s vaccine candidate, developed in partnership with BioNTech, delivered 90% efficacy. Pfizer managed to stay ahead of Moderna by reporting strong results from the
Wall Street started the week on a strong note as investors cheered news of encouraging data from late-stage trials of the covid-19 vaccine candidate being developed by Pfizer and BioNTech. The companies disclosed that their vaccine candidate is more than 90% effective in treating patients suffering from coronavirus. The companies also signed deals with various countries for
US stocks started the election week with a bang, as investors looked forward to the end of uncertainty. As the week progressed, Democratic party nominee Joe Biden consolidated his lead, and the Republicans took control of the Senate. The markets responded positively to the developments; even as incumbent President Donald Trump tried to disrupt the
Wall Street started the week with massive losses as coronavirus cases spiked in the US and Europe. Investor sentiment remained tepid as various European countries reinforced lockdown measures, fueling concerns over a slowdown in the rebound of the global economy. The week also ended on a downbeat note with major tech companies reporting earnings after
